emerging-tech-investing Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
emerging-tech-investing Sona Nanotech's Targeted Hyperthermia Therapy To Be Presented at the International 19th Canadian Melanoma Conference
Sona Nanotech's THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal
emerging-tech-investing Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update
Sona Nanotech Closes Private Placement Financing to Raise $1,500,000 in Gross Proceeds and Announces Additional Financing
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study
LAURION Reports Additional High-Grade Gold, Silver and Zinc Intersections at Ishkoday A-Zone/McLeod/CRK Zones, Confirming Structural Continuity Along the Mineralized Corridor
Alrajhi Medicine to Digitize its Healthcare Operations with Oracle to Foster Better Patient and Staff Experiences
Zscaler 2026 AI Threat Report: 91% Year-over-Year Surge in AI Activity Creates Growing Oversight Gap for Global Enterprises
